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Summary Background. Papillon–Lefevre syndrome (PLS; OMIM 245000) and Haim–Munk
syndrome (HMS; OMIM 245010), which are both characterized by palmoplantar
hyperkeratosis and periodontitis, are phenotypic variants of the same disease caused
by mutations of the cathepsin C (CTSC) gene.
Aim. To identify putative genetic modifying factors responsible for the differential
development of the PLS or HMS phenotypes, we investigated two Hungarian patients
with different phenotypic variants (PLS and HMS) but carrying the same homozy-
gous nonsense CTSC mutation (c.748C/T; p.Arg250X).
Methods. To gain insights into phenotype-modifying associations, whole exome
sequencing (WES) was performed for both patients, and the results were compared
to identify potentially relevant genetic modifying factors.
Results. WES revealed two putative phenotype-modifying variants: (i) a missense
mutation (rs34608771) of the SH2 domain containing 4A (SH2D4A) gene encoding
an adaptor protein involved in intracellular signalling of cystatin F, a known inhibi-
tor of the cathepsin protein, and (ii) a missense variant (rs55695858) of the odorant
binding protein 2A (OBP2A) gene, influencing the function of the cathepsin protein
through the glycosyltransferase 6 domain containing 1 (GLT6D1) protein.
Conclusion. Our study contributes to the accumulating evidence supporting the
clinical importance of phenotype-modifying genetic factors, which have high poten-
tial to aid the elucidation of genotype–phenotype correlations and disease prognosis.
Introduction
Papillon–Lefevre syndrome (PLS; OMIM 245000) and
Haim–Munk syndrome (HMS; OMIM 245010) are
both characterized by overlapping dermatological and
dental symptoms, including hyperkeratosis of the
palms and soles and severe periodontitis.1,2 Patients
with PLS can also develop mild mental retardation,
calcification of the dura mater, hyperhidrosis and
increased susceptibility to infections.3–5 Specific fea-
tures of HMS include pes planus, arachnodactyly,
acro-osteolysis and onychogryphosis.6–8 The preva-
lence of PLS is approximately four cases per million,
and to date, approximately 300 cases have been
reported worldwide. Parental consanguinity has been
noted in > 50% of these cases.4,9 The prevalence of
HMS is approximately one case per million, and the
majority of reported cases are descendants of a few
consanguineous families from a religious isolate in
Cochin, India. One unrelated Brazilian patient has also
been reported. To date, < 100 HMS cases have been
reported in the literature.6–8 The ratio of affected
males to females is 1 : 1 for both syndromes. PLS and
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HMS are both inherited in an autosomal recessive
manner and develop as a consequence of mutations in
the cathepsin C (CTSC) gene.10,11 Currently, 89 CTSC
gene mutations have been identified.1,12 The majority
of these mutations have been detected in patients with
PLS, whereas only 4% have been associated with
HMS.1,2,7,8
In light of the reported PLS and HMS phenotypes
and the associated CTSC mutations, we hypothesized
that PLS and HMS are the same entity with different
phenotypic appearances.1 Although it is difficult to
establish genotype–phenotype correlations, the elucida-
tion of these correlations is likely to have significant
clinical relevance for the development of the different
clinical variants (PLS and HMS), the disease mecha-
nism and the development of future therapies.1
We recently investigated two Hungarian patients,
one with PLS and one with HMS, who nonetheless
carry the same homozygous nonsense mutation
(c.748C/T; p.Arg250X) of the CTSC gene.13 As there
is currently no explanation for why one mutation can
lead to these two different clinical variants (PLS and
HMS), we were interested in the identification of phe-
notype-modifying genetic factors that could facilitate
the understanding of the phenotypic differences
between these patients. In this study, whole exome
sequencing (WES) was used to identify putative pheno-
type-modifying genetic factors that could explain the
observed clinical differences between these PLS and
HMS patients carrying the same causative CTSC muta-
tion.
Methods
Patients
The clinical phenotypes of the affected patients were
reported in detail in a previous paper from our
research group.13 Briefly, Patient 1 was a Hungarian
woman who presented with the typical HMS pheno-
type; mild hyperkeratotic plaques were observed sym-
metrically on her palms and soles, while
onychogryphosis and arachnodactyly were noted on
her fingers and pes planus on her soles. Patient 2 was
a Hungarian man who presented with the classic PLS
phenotype, i.e. moderate hyperkeratosis on his palms
and soles. Both patients were missing all permanent
teeth and using a permanent dental prosthesis. In our
previous paper, we also reported the results of haplo-
type analysis, which raised the possibility that these
patients are siblings.13 It was not possible to genotype
unaffected relatives.13
DNA samples
The two previously reported Hungarian patients,
affected by PLS and HMS respectively, but carrying
the same disease-causing mutation (c.748C/T;
p.Arg250X) in the CTSC gene, were investigated.12
DNA samples from both patients were used for WES
(performed by UD-GenoMed Medical Genomic Tech-
nologies Ltd., Debrecen, Hungary; http://www.ud-ge
nomed.hu/). The quality of the DNA samples was eval-
uated by agarose-gel electrophoresis.
Whole exome sequencing
In brief, 4 µg of DNA with a concentration of 100 ng/
µL were used for library construction. A liquid chip
capture system (Agilent Research Laboratories, Santa
Clara, CA, USA) was used to efficiently enrich all
human exon regions. High-throughput deep sequenc-
ing was subsequently performed on the Illumina (San
Diego, CA, USA) platform. An exon kit (SureSelect
Human All Exon V6 Kit; Agilent) was used for library
construction and capture experiments, and a bioanaly-
ser (Model 2100; Agilent) was subsequently used to
verify the library insert size. The Illumina platform
was used for sequencing according to the effective
concentration of the library and the data output
requirements. High-throughput paired-end sequencing
(paired-end 150 bp; PE150; Agilent) was performed.
Bioinformatics analysis
After WES was completed, bioinformatics analysis was
performed, including quality assessment of sequencing
data, single-nucleotide polymorphism (SNP) detection
and whole exome association analysis.
The sequencing data quality control requirements
were as follows: sequencing error rate of each base
position < 1%, mean Q20 ratio > 90%, mean Q30
ratio > 80%, mean error rate < 0.1%, alignment rate
for sequencing reads ≤ 95% and read depth of the
base at one position ≥ 10 times.
Single nucleotide polymorphism
SNP testing was performed as follows: high-quality
sequences were aligned with the human reference
genome (GRCh37/hg19) to detect sequence variants,
and the detected variations were analysed and anno-
tated. Variants were filtered according to read depth,
allele frequency and prevalence in genomic variant
databases such as ExAc (v.0.3), ClinVar and Kaviar.
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Variant prioritization tools (PolyPhen2, SIFT, LRT,
Mutation Taster, Mutation Assessor) were used to predict
the functional impact. All the identified candidate vari-
ants were confirmed by direct sequencing (Delta Bio
2000 Ltd., Szeged, Hungary; http://www.deltabio.hu/).
Results
A comparison of the WES data from these PLS and
HMS patients carrying the same disease-causing muta-
tion (c.748C/T; p.Arg250X) in the CTSC gene identi-
fied 34 variants, which were all present in the patient
with HMS, but not in the patient with PLS, for whom
no mutation or polymorphism was found. Two of the
34 variants were suggested as putative phenotype-
modifying polymorphisms by variant prioritization
tools: the rs34608771 SNP of the SH2 domain con-
taining 4A (SH2D4A) gene and the rs55695858 SNP
of the odorant binding protein 2A (OBP2A) gene. Both
variants are common missense polymorphisms.
Pathogenicity predictions for the identified phenotype-
modifying factors are summarized in Table 1.
Discussion
Identification of the disease-causing mutations is extre-
mely important for therapy or genetic counselling, but
clinical genetics has already reached the limitations of
the direct sequencing technology, as it is unable to
answer clinically relevant questions such as genotype–
phenotype correlations or disease prognosis, or explain
the development of different clinical variants in
patients carrying the same disease-causing mutation.14
This is the case with the two PLS and HMS patients
examined here and reported previously by our work-
group.13 Although the same disease-causing CTSC
mutation was identified in both patients, the causative
mutation itself does not explain the striking pheno-
typic differences between them. To overcome this limi-
tation, identification of the putative phenotype
modifier genetic factors might be useful. Next-generation
sequencing systems have become more popular and
more widely available as their cost has decreased, and
clinical genetics has now access to these high-
throughput technologies.14 In the field of monogenic
skin diseases, ichthyosis is a good example of the clini-
cal relevance of the phenotype modifier genetic factors,
since the genetic modifiers identified to date have been
found to contribute to the variable disease phenotype
in this disease.15
The comparison of the WES data of our HMS and
PLS patients identified a putative phenotype-modify-
ing genetic variant (rs34608771 SNP) in the
SH2D4A gene, which encodes a T-cell-expressed
adapter protein that is expressed in T cells, B cells,
macrophages and dendritic cells.16 SH2D4A regulates
T-cell receptor signal transduction in T cells, and in
humans, its expression in T cells is increased in
response to T-cell activation.16 SH2D4A is linked to
cathepsin C via cystatin F, a cysteine-protease inhibi-
tor expressed selectively in immune cells, such as T
cells, natural killer cells and dendritic cells.17 The
rs34608771 polymorphism of the SH2D4A gene has
not been associated previously with any human dis-
ease; to our knowledge, this is the first study linking
it to the development of the HMS clinical variant and
raises its putative association with the phenotypic dif-
ferences between PLS and HMS (Fig. 1).
The other putative phenotype-modifying genetic
variant (rs55695858 SNP) is located within the
OBP2A gene, which encodes an odorant-binding car-
rier protein that has a known environmental biosen-
sor function. The OBP2A protein is expressed in the
nasal structures, salivary and lachrymal glands, and
lungs, and thus, has an oral sphere profile.18
OBP2A interacts with the glycosyltransferase 6
domain containing 1 (GLT6D1) protein, encoded by
the GLT6D1 gene, which has been identified as a
susceptibility locus for periodontitis by genome-wide
association studies, and this association has been
confirmed by several previous studies.19 Although
genetic variants of the OBP2A gene have been
implicated in influencing the substrate-binding speci-
ficity of the encoded protein, none have previously
been associated with the development of a human
disease.20,21 As periodontitis is a major feature of
the PLS and HMS phenotypes, we suggest that the
rs55695858 SNP of the OBP2A gene might
Table 1 Pathogenicity predictions and clinical associations of the
identified phenotype-modifying genetic factors.
SNP rs34608771 rs55695858
Gene SH2D4A OBP2A
Location Exonic Exonic
Variant type Missense Missense
Analysis
SIFT Tolerated Tolerated
Polyphen2 Benign Possibly damaging
MutationTaster Polymorphism Polymorphism
Clinical
associations
Development of the
HMS phenotype
Development of the
HMS phenotype
Reference This study This study
HMS, Haim–Munk syndrome; SNP, single nucleotide polymor-
phism.
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contribute to the phenotypic differences observed
between PLS and HMS patients (Fig. 1).
Conclusion
Our study aimed to explain the phenotypic differences in
PLS and HMS patients carrying the same disease-causing
CTSC mutation by identifying phenotype-modifying
genetic polymorphisms. It should be noted that, in addi-
tion to genetic factors, environmental or lifestyle factors
might also contribute to the phenotypic differences
between PLS and HMS. Further functional studies are
needed to prove the clinical relevance of the identified
phenotype-modifying genetic factors and to describe the
underlying mechanism that explains their phenotype-
modifying roles. Our study contributes to the accumulat-
ing evidence supporting the clinical importance of phe-
notype-modifying genetic factors and their potential to
facilitate the elucidation of genotype–phenotype correla-
tions or disease prognosis.22
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What’s already known about this topic?
• PLS and HMS are caused by mutations of the
CTSC gene.
• They are characterized by overlapping clinical
features.
• They are phenotypic variants of the same dis-
ease.
What does this study add?
• Our study revealed two putative phenotype-
modifying variants.
• The first was a missense mutation of the
SH2D4A gene involved in the intracellular sig-
nalling of the cystatin F, a known inhibitor of
CTSC.
• The second was a missense variant of the
OBP2A gene influencing CTSC through GLT6D1.
References
1 Nagy N, Valyi P, Zs Csoma et al. CTSC and Papillon-
Lefevre syndrome: detection of recurrent mutations in
Hungarian patients, a review of published variants and
database update. Mol Gen Genom Med 2014; 2: 217–28.
2 Selvaraju V, Markandaya M, Prasad PV et al. Mutation
analysis of the cathepsin C gene in Indian families with
Papillon-Lefevre syndrome. BMC Med Genet 2003; 4: 5.
3 Dalgic B, Bukulmez A, Sari S. Eponym: Papillon-Lefevre
syndrome. Eur J Pediatr 2011; 170: 689–91.
4 Gorlin RJ, Sedano H, Anderson VE. The syndrome of
palmar-plantar hyperkeratosis and premature periodontal
destruction of the teeth: a clinical and genetic analysis of
the Papillon-Lefevre syndrome. J Pediatr 1964; 65:
895–908.
5 Haneke E. The Papillon-Lefevre syndrome: keratosis
palmoplantaris with periodontopathy: report of a case
and review of the cases in the literature. Hum Genet
1979; 51: 1–35.
6 Haim S, Munk J. Keratosis palmo-plantaris congenita,
with periodontosis, arachnodactyly and a peculiar
deformity of the terminal phalanges. Br J Dermatol 1965;
77: 42–54.
7 Hart TC, Hart PS, Bowden DW et al. Mutations of the
cathepsin C gene are responsible for Papillon-Lefevre
syndrome. J Med Genet 1999; 36: 881–7.
8 Papillon PH, Lefevre P. Deux cas de keratodermie
palmaire et plantaire symetrique familiale (Maladie de
Meleda) chez le frere et la soeur. Coexistence dans les
Figure 1 Schematic of the proposed
mechanisms of the identified phenotype-
modifying factors.
ª 2020 The Authors. Clinical and Experimental Dermatology published by
John Wiley & Sons Ltd on behalf of British Association of Dermatologists
558 Clinical and Experimental Dermatology (2020) 45, pp555–559
Phenotype modifiers responsible for the development of PLS or HMS  E. M. Pap et al.
deux cas d’alterations dentaires graves. Bull Soc Fr
Dermatol Syphiligr 1924; 31: 82–7.
9 Hewitt C, McCormick D, Linden G et al. The role of
cathepsin C in Papillon-Lefevre syndrome, prepubertal
periodontitis, and aggressive periodontitis. Hum Mutat
2004; 23: 222–8.
10 Adkison AM, Raptis SZ, Kelley DG et al. Dipeptidyl
peptidase I activates neutrophil-derived serine proteases
and regulates the development of acute experimental
arthritis. J Clin Invest 2002; 109: 363–71.
11 Toomes C, James J,WoodAJ et al. Loss-of-functionmutations
in the cathepsin C gene result in periodontal disease and
palmoplantar keratosis.Nat Genet 1999;23: 421–4.
12 Sulak A, Toth L, Farkas K et al. One mutation, two
phenotypes: a single nonsense mutation of the CTSC
gene causes two clinically distinct phenotypes. Clin Exp
Dermatol 2016; 41: 190–5.
13 Machado RA, Cuadra-Zelaya FJM, Martelli-Junior H et al.
Clinical and molecular analysis in Papillon-Lefevre
syndrome. Am J Med Genet A 2019; 179: 2124–31.
14 Jarinova O, Ekker M. Regulatory variations in the era of
next-generation sequencing: implications for clinical
molecular diagnostics. Hum Mutat 2012; 33: 1021–30.
15 Kiritsi D, Valari M, Fortugno P et al. Whole-exome
sequencing in patients with ichthyosis reveals modifiers
associated with increased IgE levels and allergic
sensitizations. J Allergy Clin Immunol 2015; 135:
280–3.
16 Lapinski PE, Oliver JA, Kamen LA et al. Genetic analysis
of SH2D4A, a novel adapter protein related to T cell-
specific adapter and adapter protein in lymphocytes of
unknown function, reveals a redundant function in T
cells. J Immunol 2008; 181: 2019–27.
17 Hamilton G, Colbert JD, Schuettelkopf AW et al. Cystatin
F is a cathepsin C-directed protease inhibitor regulated
by proteolysis. EMBO J 2008; 27: 499–508.
18 Lacazette E, Gachon AM, Pitiot G. A novel human
odorant-binding protein gene family resulting from
genomic duplicons at 9q34: differential expression in the
oral and genital spheres. Hum Mol Genet 2000; 9:
289–301.
19 Schaefer AS, Richter GM, Nothnagel M et al. A genome-
wide association study identifies GLT6D1 as a
susceptibility locus for periodontitis. Hum Mol Genet
2010; 19: 553–62.
20 Tomassini Barbarossa I, Ozdener MH, Love-Gregory L
et al. Variant in a common odorant-binding protein gene
is associated with bitter sensitivity in people. Behav Brain
Res 2017; 329: 200–4.
21 Tcatchoff L, Nespoulous C, Pernollet JC et al. A single
lysyl residue defines the binding specificity of a human
odorant-binding protein for aldehydes. FEBS Lett 2006;
580: 2102–8.
22 Lee DS, Park J, Kay KA et al. The implications of human
metabolic network topology for disease comorbidity. Proc
Natl Acad Sci USA 2008; 105: 9880–5.
Clinical and Experimental Dermatology (2020) 45, pp555–559 559ª 2020 The Authors. Clinical and Experimental Dermatology published by
John Wiley & Sons Ltd on behalf of British Association of Dermatologists
Phenotype modifiers responsible for the development of PLS or HMS  E. M. Pap et al.
